Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study

J. Slatinska, A. Slavcev, E. Honsova, P. Hruba, I. Kratochvilova, T. Rohal, O. Viklicky,

. 2018 ; 92 Suppl 2 (-) : 47-50. [pub] -

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035039

A novel therapeutic approach to refractory acute antibody-mediated rejection (AMR) in kidney transplant recipients was applied in 23 patients based on administration of Bortezomib, intravenous corticosteroids, plasmapheresis and Rituximab. Application of Bortezomib regimen led to diminishing of donor-specific antibodies (DSA) to HLA-B (P = 0.004) and HLA-DR (P = 0.0005), but not to HLA-A (P = 0.106) and HLA-DQ antigens (P = 0.18). Patients with good clinical response to treatment had significantly better allograft survival than recipients with continuing deterioration of graft function (P = 0.019). Graft survival after therapy of refractory AMR was significantly worse than survival after first transplantation and was comparable with outcomes after retransplantation. In conclusion, therapy with Bortezomib was well tolerated and effective in decreasing the levels of HLA-B and -DR antibodies, however, was not successful in depleting HLA-A and -DQ DSA.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035039
003      
CZ-PrNML
005      
20191014101254.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/tan.13387 $2 doi
035    __
$a (PubMed)30168284
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Slatinska, Janka $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
245    10
$a Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study / $c J. Slatinska, A. Slavcev, E. Honsova, P. Hruba, I. Kratochvilova, T. Rohal, O. Viklicky,
520    9_
$a A novel therapeutic approach to refractory acute antibody-mediated rejection (AMR) in kidney transplant recipients was applied in 23 patients based on administration of Bortezomib, intravenous corticosteroids, plasmapheresis and Rituximab. Application of Bortezomib regimen led to diminishing of donor-specific antibodies (DSA) to HLA-B (P = 0.004) and HLA-DR (P = 0.0005), but not to HLA-A (P = 0.106) and HLA-DQ antigens (P = 0.18). Patients with good clinical response to treatment had significantly better allograft survival than recipients with continuing deterioration of graft function (P = 0.019). Graft survival after therapy of refractory AMR was significantly worse than survival after first transplantation and was comparable with outcomes after retransplantation. In conclusion, therapy with Bortezomib was well tolerated and effective in decreasing the levels of HLA-B and -DR antibodies, however, was not successful in depleting HLA-A and -DQ DSA.
650    _2
$a hormony kůry nadledvin $x terapeutické užití $7 D000305
650    _2
$a dospělí $7 D000328
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a rejekce štěpu $x krev $x diagnóza $x imunologie $x patologie $7 D006084
650    12
$a přežívání štěpu $7 D006085
650    _2
$a HLA antigeny $x genetika $x imunologie $7 D006680
650    _2
$a testování histokompatibility $x metody $7 D006650
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a isoprotilátky $x krev $7 D007518
650    12
$a transplantace ledvin $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a bezpečnost pacientů $7 D061214
650    _2
$a pilotní projekty $7 D010865
650    _2
$a plazmaferéza $x metody $7 D010956
650    _2
$a prognóza $7 D011379
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a dárci tkání $7 D014019
650    _2
$a homologní transplantace $7 D014184
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Slavcev, Antonij $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Honsova, Eva $u Department of Clinical and Transplantation Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Hruba, Petra $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kratochvilova, Iva $u Department of Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Rohal, Tomas $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Viklicky, Ondrej $u Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
773    0_
$w MED00195031 $t HLA $x 2059-2310 $g Roč. 92 Suppl 2, č. - (2018), s. 47-50
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30168284 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014101718 $b ABA008
999    __
$a ok $b bmc $g 1451699 $s 1073589
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 92 Suppl 2 $c - $d 47-50 $e - $i 2059-2310 $m HLA $n HLA $x MED00195031
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options